Northwest Clinical Center for Type 1 Diabetes - TrialNet

$799,561U01FY2013DKNIH

Benaroya Research Inst At Virginia Mason, Seattle WA

Investigators

Linked publications, trials & patents

Paper 39670998 Paper 39560746 Paper 39167668 Paper 39137044 Paper 39103721 Paper 38712386 Paper 38621411 Paper 37940642 Paper 37000695 Paper 36920087 Paper 36326757 Paper 36175392 Paper 35998266 Paper 35880956 Paper 35524749 Paper 35041021 Paper 34853027 Paper 34850014 Paper 34642772 Paper 34620616 Paper 34551936 Paper 34338806 Paper 34127860 Paper 33658358 Paper 33496819 Paper 33441381 Paper 33424774 Paper 33277338 Paper 32844178 Paper 32833543 Paper 32747817 Paper 32669415 Paper 32573495 Paper 32502242 Paper 32457058 Paper 32404353 Paper 32248243 Paper 32019856 Paper 32003110 Paper 31982961 Paper 31937610 Paper 31867614 Paper 31794865 Paper 31768570 Paper 31558546 Paper 31180194 Paper 31167877 Paper 30967424 Paper 30894366 Paper 30891858 Paper 30830871 Paper 30830868 Paper 30730939 Paper 30709843 Paper 30629603 Paper 30612319 Paper 30552130 Paper 30405601 Paper 30275285 Paper 30232284 Paper 30167735 Paper 30089716 Paper 30061316 Paper 30012675 Paper 29931415 Paper 29925930 Paper 29851415 Paper 29769238 Paper 29429978 Paper 29171129 Paper 29164254 Paper 29040630 Paper 29025879 Paper 28956083 Paper 28860125 Paper 28821222 Paper 28770323 Paper 28707353 Paper 28531305 Paper 28520980 Paper 28500393 Paper 28226181 Paper 28202550 Paper 28177779 Paper 28053319 Paper 27704166 Paper 27579340 Paper 27456836 Paper 27422577 Paper 27385327 Paper 27362539 Paper 27208341 Paper 27114212 Paper 26991448 Paper 26822082 Paper 26692253 Paper 26375197 Paper 26336066 Paper 26077017 Trial NCT00004984

Abstract

DESCRIPTION (provided by applicant): This application for re-selection as a Diabetes TrialNet Clinical Center consist of (1) a proposed clinical trial (2) a description of our activities in the conduct of Type 1 diabetes clinical research (3) a description of our recruitment efforts, and (4) a description of the clinical facilities available for the conduct of TrialNet protocols. Previous studies have demonstrated that short term administration of anti-T cell, anti-B cell, and antigen-based therapy at least temporarily alters the course of beta cell destruction. Extending therapeutic benefits will likely require combination therapy such as elimination of the T effector response, protection of beta cells, activation of T regulatory cells, and enhancement of insulin action. TrialNet and other groups have successfully developed a platform to rapidly test therapies in newly diagnosed subjects. We believe that systematic testing of a wide variety of agents and careful use of clinical samples for exploratory analysis of data is the only way forward. To that end, we propose to test the effect of Tocilizumab (Anti-IL6Rab) on recently diagnosed subjects with Type 1 diabetes to determine whether it will preserve beta cell function. Our selection of Anti- IL6Rab is based on the following observations: (1) mechanistically, Anti-IL6Rab may have several important effects both as a therapy promoting the activity of T-regulatory cells allowing prolonged remission of disease, and as an anti-inflammatory altering the local pancreatic inflammatory infiltrate allowing enhanced beta cell function and/or allowing enhanced insulin action, (2) there is clinical safety data on the use of Anti-IL6Rab including data in children, (3) Anti-IL6Rab is clinically efficacious in treatment of other autoimmune diseases. The specific aims of this trial are to: ( Demonstrate the short term safety of Anti-IL6Rab in newly diagnosed patients, ( Demonstrate the efficacy of Anti-IL6Rab in newly diagnosed patients with respect to preservation of beta cell function ( Test the impact of Anti-IL6Rab therapy and response to therapy on measures associated with our primary hypothesized mechanism of action - promoting the activity of T regulatory cells.

View original record on NIH RePORTER →